115180 - Qurient Co., Ltd.

115180 Summary
Biopharma
Stock Price & Overview
₩23,050 +3,400 (+17.30%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩23,050  ≈ US$16  ·  Market cap ₩0.9tn (≈ $618m)

Material matter affecting investment judgment (clinical trial plan approval)

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항(임상시험계획승인신청등결정) (만성 이식편대숙주질환 환자 대상 Q702 단독치료요법의 스페인 임상 제1b상 임상시험계획 승인)